The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

AbbVie (ABBV) closed the latest trading day at $213.59, indicating a -1.42% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day.

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:ABBV) in the last three months. The table below provides a concise overview of ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Some of the major U.S. indexes began recovering on Wednesday, following the Trump ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...